Objective: To map the different personal positions of Guinean people regarding vaccination against Ebola.
Methods: From January to April 2016, 304 adults in Guinea were presented with 48 vignettes depicting situations in which getting vaccinated would be possible. These situations varied as a function of the constructs of health-protective behavior theories. The participants indicated the likelihood they would get vaccinated in each case.
Results: Seven qualitatively different positions were found: Always Vaccinate (38%), Never Vaccinate (25%), Hesitant (19%), Depends on Cost Only (7%), Depends on Neighbors' Attitude and Cost (5%), Mainly Depends on Risk (4%), and Mistrust of Cheap Vaccines (2%).
Conclusion: The diversity of Guinean people's positions implies that Ebola vaccination campaigns in Guinea, and probably in other sub-Saharan African countries, must not be "one size fits all," but must be multifaceted and tailored in design and implementation to match the diversity of these people's needs and views.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284512 | PMC |
| http://dx.doi.org/10.1080/21645515.2018.1480236 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cryptosporidium spp. prevalence in the general population in Guinea: first large-scale screening study.
Parasite
November 2024
CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Centre d'Infection et d'Immunité de Lille, Université de Lille, 59000 Lille, France - Délégation à la Recherche Clinique et à l'Innovation, Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille Catholic University, 59000 Lille, France.
Article Synopsis
- Cryptosporidium is a major cause of diarrheal deaths in children in Africa and Asia, but its prevalence in Guinea is not well understood.
- A study collected fecal samples from 834 individuals in Conakry, finding a low prevalence of 0.12%, mainly in adults, with the identified species being Cryptosporidium hominis.
- This research is the first to report on Cryptosporidium's presence in Guinea, highlighting the need for more studies to understand its impact on public health.
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches).
BMC Med
November 2024
World Health Organization, Geneva, Switzerland.
Background: Zaire Ebolavirus disease (EVD) outbreaks can be controlled using rVSV-ZEBOV vaccination and other public health measures. People in high-risk areas may have pre-existing antibodies from asymptomatic Ebolavirus exposure that might affect response to rVSV-ZEBOV. Therefore, we assessed the impact pre-existing immunity had on post-vaccination IgG titre, virus neutralisation, and reactogenicity following vaccination.
View Article and Find Full Text PDFUnderstanding the longitudinal trends (2005-2018) and multilevel risk factors of complementary feeding in Guinea.
Matern Child Nutr
January 2025
Department of Nutritional Sciences, College of Health and Human Development, The Pennsylvania State University, University Park, State College, Pennsylvania, USA.
This study aimed to define complementary feeding trends in Guinea from 2005 to 2018 and complementary feeding risk factors at the individual, household, and community levels. Data from 2005 to 2018 demographic health surveys (DHS) and Multiple Indicator Cluster Surveys were used to describe complementary feeding trends in Guinea. The most recent DHS was used to examine complementary feeding risk factors at the individual, household, and community levels.
View Article and Find Full Text PDFPerformance of an envelope glycoprotein-based multiplex immunoassay for Ebola virus antibody detection in a cohort of Ebola virus disease survivors.
J Virol Methods
January 2025
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA. Electronic address:
Serological surveillance in animal and human hosts can be a cost-effective strategy for orthoebolavirus detection, but is challenged by accurate estimates of seroprevalence, potential pauci-symptomatic disease presentation, and antigenic cross-reactivity. Here, we describe the use of an envelope glycoprotein (GP)-based multiplex microsphere immunoassay, consisting of nine filovirus GP antigens for the detection of anti-Ebola virus (EBOV) antibodies in a well-characterized cohort of Guinean Ebola virus disease (EVD) survivors and contacts from the 2013 - 2016 West African EVD outbreak. We examined sensitivity and specificity for the detection of anti-EBOV antibodies by GP expressed as recombinant trimeric ectodomains, yielding an assay performance of 95.
View Article and Find Full Text PDFEbola virus circulation in a non-epidemic Guinean rural area: A mixed-method approach to assessing endemicity.
Int J Infect Dis
September 2024
Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG), Gamal Abdel Nasser University, Conakry, Republic of Guinea; Faculté des Sciences et Techniques de la Santé, Gamal Abdel Nasser University, Conakry, Republic of Guinea; Department of Pharmaceutical and Biological Sciences, Gamal Abdel Nasser University, Conakry, Republic of Guinea.
Objectives: This study aimed to investigate the prevalence of orthoebolavirus antibodies in Madina Oula, a non-epidemic rural area in Guinea, in 2022.
Methods: A cross-sectional study was conducted from March 14 to April 3, 2022 involving recording household and socio-demographic characteristics, lifestyle data, and collecting dried blood spots from 878 individuals in 235 households. Dried blood spots were tested using multiplex serology to detect antibodies to different orthoebolaviruses: Ebola virus, Bundibugyo virus, Sudan virus, Reston virus, and Bombali virus.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!